Moffitt Cancer Center
Moffitt is Florida's cancer centre and the leading US site for TIL therapy and evolutionary ('adaptive') therapy research.
Lifileucel pivotal trials (Sarnaik), adaptive therapy (Gatenby), immunotherapy programme, ORIEN data network.
- TIL therapy
- Adaptive therapy
- Immuno-oncology
Amod Sarnaik led the pivotal lifileucel trial that produced the first approved TIL therapy.
Head and neck oncologist who helped define the genomic subtypes of HPV-positive and HPV-negative disease.
Eric Haura is a lung cancer physician-scientist who maps drug-target signalling with proteomics.
Led the ZUMA-7 trial that put CAR-T ahead of transplant in relapsed large B-cell lymphoma.
Hatem Soliman is a breast oncologist leading immunotherapy and genomic-assay trials, including in triple-negative disease.
Patrick Hwu is an immunotherapy pioneer who trained with Rosenberg and now leads Moffitt.
Applies evolutionary game theory to cancer treatment, dosing drugs to control rather than eradicate resistant clones.
Shari Pilon-Thomas is the immunologist behind Moffitt's TIL manufacturing and the biology of who responds.
ZUMA-7 rewrote second-line treatment for aggressive lymphoma: patients whose disease returns within a year of R-CHOP should be offered CAR-T rather than salvage chemotherapy and transplant. It is also one of the few cell-therapy trials to show an overall survival benefit despite crossover. Patients relapsing later than 12 months were not studied and transplant remains standard for them if chemosensitive.
Lifileucel proved that Steven Rosenberg's decades-old TIL concept could be industrialised into a licensed product and gave patients with checkpoint-refractory melanoma, who otherwise have few options, a chance of durable remission. It is the first cell therapy approved for any solid tumour. The treatment requires surgery to harvest tumour, hospitalisation for lymphodepletion and IL-2, and specialised centres, so its reach is limited.
ZUMA-1 showed that CAR-T can cure a meaningful fraction of adults whose aggressive lymphoma no longer responds to chemotherapy, a group with a historical median survival of about six months (SCHOLAR-1). Axi-cel became the first CAR-T approved for lymphoma and later the first to beat standard second-line therapy in ZUMA-7. The comparatively high neurotoxicity of CD28-costimulated products was also first characterised here.
Pages like this
not linked directly; found by shared links- TrialC-144-01
Shares Amod A. Sarnaik, C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed, Lifileucel, TIL therapy.
- CompanyIovance Biotherapeutics
Shares C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed, Lifileucel, TIL therapy, Melanoma.
- PersonSteven A. Rosenberg
Shares C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed, Lifileucel, TIL therapy, Melanoma.
- Key paperRohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma
Shares C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed, Lifileucel, TIL therapy, Melanoma.
- TrialZUMA-7
Shares Frederick L. Locke, ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma, ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early.
- PairingPD-1 failure → TIL therapy
Shares Lifileucel, TIL therapy, Melanoma.
- ProductAxicabtagene ciloleucel
Shares Frederick L. Locke, ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma, ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early.
- TermDrug resistance (primary and acquired)
Shares Robert A. Gatenby, Evolution-guided 'adaptive therapy' dosing tested in randomised phase 2 trials, Autonomous closed-loop adaptive therapy driven by blood tests and evolutionary models, Clonal evolution & minimal residual disease.